Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass

GLP-1 Receptor Agonist-Induced Muscle Mass Evaluation and Retention

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07272837

Acronym

GLIMMER

Enrollment

Registered

2025-12-09

Start date

2026-05-15

Completion date

2028-04-30

Last updated

2026-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, GLP-1, Obesity, Semaglutide, Type 2 Diabetes

Keywords

Semaglutide, Type 2 Diabetes, Diabetes, Obesity, Body Composition, Muscle Mass, Skeletal Muscle Mass, Cardiac Muscle Mass, GLP-1 Receptor Agonist, GLP-1, MRI, Magnetic Resonance Imaging

Brief summary

The aim of this study is to use advanced MRI scans to track changes in both muscle and fat in the body and heart over a 12-month period in individuals starting semaglutide. By doing so, we hope to gain a clearer understanding of how semaglutide affects muscle health and function. Our goal is to ensure the medication supports long-term well-being, particularly for people who may be at higher risk of muscle loss. This study involves (3) in-person study visits. At each visit, participants will be asked to: * Undergo magnetic resonance imaging (MRI) while resting and during exercise to take pictures of their heart, abdomen, and legs. * Complete tests to assess balance, sit-to-stand, walking speed, and handgrip strength. * Complete questionnaires related to demographics, health information, physical activity, and nutrition. * Have a blood sample collected from a vein in your arm. * Have your blood levels assessed through three finger pricks. * Complete three days of food records.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Adults 18-80 years of age * Starting semaglutide for type 2 diabetes or weight loss * Able to safely undergo an MRI scan (including meeting the physical requirements for MRI equipment)

Exclusion criteria

* Current use of semaglutide for more than 2 weeks * Major recent heart issues or other severe health conditions * Concerns related to MRI use (including magnetic implants, pacemaker, severe claustrophobia) * Dependence on a mobility aid (unable to participate in exercise MRI)

Design outcomes

Primary

Measure	Time frame
Changes in skeletal and cardiac muscle mass	12 months

Countries

Canada

Contacts

CONTACTKrista Jong, RD, BSc

glimmer@ualberta.ca780-492-9010

Outcome results